Cummings J L, Masterman D L
Department of Neurology, University of California at Los Angeles, School of Medicine, West Los Angeles Veterans Affairs Medical Center, 90095-1769, USA.
J Clin Psychiatry. 1998;59 Suppl 13:23-30.
Alzheimer's disease affects multiple domains of human brain function and has neuropsychological, neuropsychiatric, and neurologic manifestations. Behavioral changes should be assessed as part of a comprehensive evaluation of the effects of cholinergic treatment of Alzheimer's disease. The psychometric properties, origin, source of behavioral information, content, and administration requirements of tools used to assess behavior in Alzheimer's disease affect the type of information garnered and the conclusions that can be derived. Assessment of drug-related behavioral changes can be affected by spontaneous remission of neuropsychiatric symptoms, differing baseline severity of behavioral abnormalities, uncertain magnitude of expected treatment effects, and by the influence of disease stages, concurrent medications, and comorbid conditions. Cholinergic therapies ameliorate behavioral alteration in Alzheimer's disease, and changes in behavior should be monitored when such therapy is initiated.
阿尔茨海默病会影响人类大脑功能的多个领域，并具有神经心理学、神经精神学和神经学表现。行为改变应作为对阿尔茨海默病胆碱能治疗效果进行全面评估的一部分加以评估。用于评估阿尔茨海默病患者行为的工具的心理测量特性、起源、行为信息来源、内容及使用要求，会影响所获取信息的类型以及能得出的结论。药物相关行为改变的评估可能会受到神经精神症状的自发缓解、行为异常基线严重程度不同、预期治疗效果大小不确定，以及疾病阶段、同时使用的药物和合并症的影响。胆碱能疗法可改善阿尔茨海默病患者的行为改变，在开始此类治疗时应监测行为变化。
